1st Quarter - Report

ALSTON & BIRD LLP for TRAVERE THERAPEUTICS

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care; H.R.482/S.350, Newborn Screening Saves Lives Act Reauthorization; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.2617, the Consolidated Appropriations Act, 2023.

LobbyistCovered position, as disclosed
ELINOR HILLER —
JAMES PATRICK PALUSKIEWICZ —
MARK RAYDER —
EMILY A SHAW —
ROBERT SIGGINS —
MARILYN K YAGER —

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); SENATE

Bills named: H.R. 2617 (118th), H.R. 7506 (118th), S. 350 (118th), H.R. 482 (118th)

Medicare/Medicaid MMM

H.R.366, Protecting Access to Post-COVID-19 Telehealth Act and related legislation; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to Medicare Part B and Part D drug policies and access to therapies for patients with rare diseases; H.R.2617, the Consolidated Appropriations Act, 2023.

LobbyistCovered position, as disclosed
ELINOR HILLER —
JAMES PATRICK PALUSKIEWICZ —
MARK RAYDER —
EMILY A SHAW —
ROBERT SIGGINS —
MARILYN K YAGER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 7506 (118th), H.R. 2617 (118th), H.R. 366 (118th), H.R. 5376 (118th)

Pharmacy PHA

Legislation regarding drug pricing, value, and reimbursement; H.R.3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R.19, Lower Costs, More Cures Act of 2021; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R.1629, Fairness in Orphan Drug Exclusivity Act; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.

LobbyistCovered position, as disclosed
ELINOR HILLER —
JAMES PATRICK PALUSKIEWICZ —
MARK RAYDER —
EMILY A SHAW —
ROBERT SIGGINS —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE

Bills named: H.R. 3 (118th), H.R. 19 (118th), H.R. 7506 (118th), H.R. 2617 (118th), H.R. 5376 (118th), S. 4348 (118th), H.R. 6963 (118th), H.R. 7667 (118th), H.R. 1629 (118th)

Medical/Disease Research/Clinical Labs MED

H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.1730/S.670, Speeding Therapy Access Today Act; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.

LobbyistCovered position, as disclosed
ELINOR HILLER —
JAMES PATRICK PALUSKIEWICZ —
MARK RAYDER —
EMILY A SHAW —
ROBERT SIGGINS —
MARILYN K YAGER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Bills named: S. 4348 (118th), H.R. 7506 (118th), H.R. 7667 (118th), H.R. 6963 (118th), S. 670 (118th), H.R. 1730 (118th), H.R. 2617 (118th)

Taxation/Internal Revenue Code TAX

Issues related to Sec. 138141 of H.R.5376, to reduce incentives for clinical testing to develop biopharmaceuticals for individuals suffering from rare/orphan diseases; legislation regarding tax treatment of net operating losses; H.R.2617, the Consolidated Appropriations Act, 2023.

LobbyistCovered position, as disclosed
MARK RAYDER —
ROBERT SIGGINS —
CAROLYN E SMITH —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2617 (118th), H.R. 5376 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.